Streetbeat News

ROIV

Roivant Sciences Ltd.

Industry

Biotechnology

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Open

11.86

Mkt cap

8.8B

Volume

4.5M

High

12.16

P/E Ratio

2.18

52-wk high

13.05

Low

11.83

Div yield

N/A

52-wk low

9.69

Roivant Sciences is advancing its drug development through its 'Vant' model, focusing on late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat. The company aims for significant milestones by 2025 and enhances shareholder value through strategic divestitures, such as Dermavant's sale to Organon for $1.2 billion.

Portfolio Pulse from

December 04, 2024 | 1:45 pm

Roivant Sciences Ltd. (ROIV) held its Q2 2024 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

November 12, 2024 | 8:00 pm

Roivant Sciences Ltd. (ROIV) reported a Q2 loss of $0.29 per share, missing the Zacks Consensus Estimate of a $0.21 loss.

Portfolio Pulse from

November 12, 2024 | 2:45 pm

Dermavant presented final data from the ADORING 3 LTE study on VTAMA cream, showing 51.9% of patients achieved complete disease clearance and remained treatment-free for about 80 days. The FDA PDUFA action date is expected in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2024 | 12:06 pm

Roivant Sciences Inc. (NASDAQ:ROIV) shares are trading at $11.88, with a slight drop of 0.25%. The stock has decreased by 0.63% over the past month but increased by 38.39% over the past year. The company's P/E ratio is lower than the Biotechnology industry's aggregate P/E of 62.68, suggesting potential undervaluation or low future growth expectations.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 3:15 pm

Several healthcare stocks experienced significant price movements in Thursday's after-market session. Renovaro, AIM ImmunoTech, Phathom Pharmaceuticals, Outlook Therapeutics, Roivant Sciences, and Century Therapeutics saw gains, while Avinger, Carmell, Ainos, Theriva Biologics, 2seventy bio, and Bone Biologics experienced losses.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 8:31 pm

CNBC's 'Final Trades' featured Organon, Howmet Aerospace, and ProShares Short QQQ. Organon is acquiring Dermavant Sciences, boosting its immunodermatology portfolio. Howmet Aerospace reported strong Q2 results and raised its financial outlook. ProShares Short QQQ saw a slight decline.

Portfolio Pulse from Avi Kapoor

October 03, 2024 | 12:43 pm

Roivant Sciences and Organon have announced a merger agreement for Dermavant Sciences. Roivant has also published an investor presentation on the transaction.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 8:29 pm

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Roivant Sciences (NASDAQ:ROIV).

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:41 pm

HC Wainwright & Co. has reiterated its Buy rating on Roivant Sciences, maintaining a price target of $18. Analyst Douglas Tsao continues to show confidence in the company's potential.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 10:21 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.